Supplemental Table 1. Patients [N (%)] treated with concomitant[a] and additional[b] antihypertensive medications during the base phase of the study

	Low dose 0.1 mg/kg/day (N=33)		Medium dose 0.3 mg/kg/day (N=34)		High dose 0.7 mg/kg/day (N=34)		Total (N=101)[d]	
	Concomitant	Additional	Concomitant	Additional	Concomitant	Additional	Concomitant	Additional
Antihypertensive Agent[c]	9 (27.3)	2 (6.1)	8 (23.5)	3 (8.8)	10 (29.4)	5(14.7)	27 (26.7)	10 (9.9)
Agents acting on the renin-angiotensin system	4 (12.1)	0 (0.0)	4 (11.8)	0 (0.0)	7 (20.6)	3 (8.8)	15 (14.9)	3 (3.0)
Calcium channel blockers	4 (12.1)	1 (3.0)	5 (14.7)	2 (5.9)	2 (5.9)	4 (11.8)	11 (10.9)	7 (6.9)
Beta blocking agents	2 (6.1)	0 (0.0)	4 (11.8)	1 (2.9)	2 (5.9)	0	8 (7.9)	1 (1.0)
Diuretics	1 (3.0)	2 (6.1)	2 (5.9)	0 (0.0)	1 (2.9)	0 (0.0)	4 (4.0)	2 (2.0)
Other antihypertensive agents[e]	0 (0.0)	0 (0.0)	2 (5.9)	0 (0.0)	1 (2.9)	0 (0.0)	3 (3.0)	0 (0.0)

[a]Patients who continued their prior antihypertensive medication during the trial.

[b]Patients who initiated treatment with an additional antihypertensive medication during the trial.

[c]Every patient is counted once for each applicable medication. Patients who received multiple medications within a category are counted once for that category.

[d]Two randomized patients did not take study medication, and were excluded from the efficacy and safety analyses.

[e]Category includes the following classes: centrally-acting agents and alpha adrenergic blocking agents.